Hepatic hemodynamic study: More than just HVPG measurement.

Evaluation and staging of liver disease is essential in the clinical decision-making process of liver tumors. The severity of portal hypertension (PH) is the main prognostic factor in advanced liver disease. Performing an accurate hepatic venous pressure gradient (HVPG) measurement is not always possible, especially when veno-venous communications are present. In those complex cases, a refinement in HVPG measurement with a thorough evaluation of each of the components of PH is mandatory. We aimed at describing how some technical modifications and complementary procedures may contribute to an accurate and complete clinical evaluation to improve therapeutic decisions.

Revisión Anatómica de Sistema Venoso Intrahepático. Hematoma Intrahepático Subcapsular en Colecistectomia Laparoscópica / Anatomical Review of Intrahepatic Venous System. Subcapsular Intrahepatic Hematoma In Laparoscopic Cholecystectomy

La aparición del hematoma intrahepático subcapsular (SHI) después de la colecistectomía laparoscópica es una complicación poco frecuente. El estudio anatómico de las venas suprahepáticas nos permitió observar que existen numerosos patrones de ramificación de estos. Presentamos el caso de una mujer de 37 años que, durante la intervención de colecistectomía laparoscópica, se observa en el acto quirúrgico, la formación espontánea de hematomas subcapsulares, secundario a la tracción forzada del fondo del órgano

The appearance of subcapsular intrahepatic hematoma (SHI) after laparoscopic cholecystectomy is an infrequent complication.The anatomical study of the suprahepatic veins allowed us to observe that there are numerous branching patterns of these. We present the case of a 37-year-old female who, during the laparoscopic cholecystectomy intervention, is observed in the surgical act, the spontaneous formation of subcapsular hematomas, secondary to forced traction of the fundus of the organ

Control de la vena cava inferior retrohepática por acceso anterior en el carcinoma de células renales con trombo tumoral nivel iiia: descripción paso a paso / Retrohepatic inferior vena cava control through an anterior approach in cases of renal cell carcinoma with level iiia tumor thrombus: Step-by-step description

Objetivo: Evaluar la seguridad y eficacia de la técnica de control de la vena cava inferior retrohepática por acceso anterior (RIVCA, por retrohepatic inferior vena cava control through an anterior approach) en el carcinoma de células renales (CCR) con trombo tumoral nivel iiia.Pacientes y métodosSerie inicial de 6 casos que presentan CCR con trombo tumoral nivel iiia intervenidos de nefrectomía radical y trombectomía tumoral mediante la técnica RIVCA entre 2018-2019. El objetivo de la técnica RIVCA es obtener un control completo de la vena cava inferior retrohepática por encima de la porción craneal del trombo tumoral, pero excluyendo las venas hepáticas mayores con el fin de preservar la circulación hepatocava natural. Se proporciona la descripción paso a paso del procedimiento. Se registraron prospectivamente los rasgos de la enfermedad, así como las características y los resultados quirúrgicos.ResultadosLa nefrectomía radical y la trombectomía tumoral se completaron en todos los casos. La técnica RIVCA no aumentó significativamente el tiempo quirúrgico (rango: 14-22min). La media de sangrado estimado fue de 325cc (rango: 250-400). No se requirió transfusión de sangre intraoperatoria en ningún caso. La media de unidades de concentrados de hematíes transfundidos por paciente en el período postoperatorio fue de 1,3 (rango: 0-2). No hubo casos de embolia pulmonar intraoperatoria ni se produjeron complicaciones mayores (Clavien-Dindo III-V) en el período postoperatorio a 30 días. La estancia hospitalaria postoperatoria (mediana) fue de 8 días (rango: 5-11). (AU)

Objective: To evaluate the safety and efficacy of the retrohepatic inferior vena cava control through an anterior approach (RIVCA) technique in renal cell carcinoma (RCC) with level iiia tumor thrombus.Patients and methodsInitial series of 6 cases presenting RCC and level iiia tumor thrombus who underwent radical nephrectomy and tumor thrombectomy using the RIVCA technique between 2018-2019. RIVCA technique aims to gain complete control of the retrohepatic inferior vena cava above the cranial end of the tumor thrombus, but excluding the major hepatic veins in order to preserve the natural hepato-caval shunt. A step-by-step description of the procedure is provided. Disease features, operative characteristics, and surgical outcomes were registered prospectively.ResultsRadical nephrectomy and tumor thrombectomy were completed in all cases. RIVCA technique did not increase operative time significantly (range: 14-22min). Mean estimated blood loss was 325cc (range: 250-400). Blood transfusion was not required intraoperatively in any of the cases. Mean postoperative transfusion rate was 1.3 red blood cells packed units (range: 0-2). There were no cases of intraoperative pulmonary embolism or major complications (Clavien-Dindo III-V) in the period of 30 days postoperatively. Median postoperative length of stay was 8 days (range: 5-11). (AU)

Retrohepatic inferior vena cava control through an anterior approach in cases of renal cell carcinoma with level IIIa tumor thrombus: Step-by-step description.

OBJECTIVE: To evaluate the safety and efficacy of the retrohepatic inferior vena cava control through an anterior approach (RIVCA) technique in renal cell carcinoma (RCC) with level IIIa tumor thrombus. PATIENTS AND METHODS: Initial series of 6 cases presenting RCC and level IIIa tumor thrombus who underwent radical nephrectomy and tumor thrombectomy using the RIVCA technique between 2018-2019. RIVCA technique aims to gain complete control of the retrohepatic inferior vena cava above the cranial end of the tumor thrombus, but excluding the major hepatic veins in order to preserve the natural hepato-caval shunt. A step-by-step description of the procedure is provided. Disease features, operative characteristics, and surgical outcomes were registered prospectively. RESULTS: Radical nephrectomy and tumor thrombectomy were completed in all cases. RIVCA technique did not increase operative time significantly (range: 14-22 min). Mean estimated blood loss was 325 cc (range: 250-400). Blood transfusion was not required intraoperatively in any of the cases. Mean postoperative transfusion rate was 1.3 red blood cells packed units (range: 0-2). There were no cases of intraoperative pulmonary embolism or major complications (Clavien-Dindo III-V) in the period of 30 days postoperatively. Median postoperative length of stay was 8 days (range: 5-11). CONCLUSIONS: The RIVCA technique applied to cases of RCC and level IIIa tumor thrombus provides complete control of the retrohepatic inferior vena cava above the tumor thrombus cranial end, while prevents intraoperative hemodynamic instability by maintaining cardiac preload through the porto-caval shunt. This technique may limit operative morbidity (intraoperative pulmonary embolism and massive hemorrhage), thus becoming a helpful adjunct to be used in cases of RCC with level IIIa tumor thrombus.

Retrohepatic inferior vena cava control through an anterior approach in cases of renal cell carcinoma with level iiia tumor thrombus: Step-by-step description. / Control de la vena cava inferior retrohepática por acceso anterior en el carcinoma de células renales con trombo tumoral nivel iiia: descripción paso a paso.

OBJECTIVE: To evaluate the safety and efficacy of the retrohepatic inferior vena cava control through an anterior approach (RIVCA) technique in renal cell carcinoma (RCC) with level iiia tumor thrombus. PATIENTS AND METHODS: Initial series of 6 cases presenting RCC and level iiia tumor thrombus who underwent radical nephrectomy and tumor thrombectomy using the RIVCA technique between 2018-2019. RIVCA technique aims to gain complete control of the retrohepatic inferior vena cava above the cranial end of the tumor thrombus, but excluding the major hepatic veins in order to preserve the natural hepato-caval shunt. A step-by-step description of the procedure is provided. Disease features, operative characteristics, and surgical outcomes were registered prospectively. RESULTS: Radical nephrectomy and tumor thrombectomy were completed in all cases. RIVCA technique did not increase operative time significantly (range: 14-22min). Mean estimated blood loss was 325cc (range: 250-400). Blood transfusion was not required intraoperatively in any of the cases. Mean postoperative transfusion rate was 1.3 red blood cells packed units (range: 0-2). There were no cases of intraoperative pulmonary embolism or major complications (Clavien-Dindo III-V) in the period of 30 days postoperatively. Median postoperative length of stay was 8 days (range: 5-11). CONCLUSIONS: The RIVCA technique applied to cases of RCC and level iiia tumor thrombus provides complete control of the retrohepatic inferior vena cava above the tumor thrombus cranial end, while prevents intraoperative hemodynamic instability by maintaining cardiac preload through the porto-caval shunt. This technique may limit operative morbidity (intraoperative pulmonary embolism and massive hemorrhage), thus becoming a helpful adjunct to be used in cases of RCC with level iiia tumor thrombus.

Automatic 3D modeling of liver segments including segmental branches of portal triad and hepatic vein based on the sectioned-images / Modelado 3D automático de segmentos hepáticos, con las ramas segmentarias de la tríada portal y la vena hepática basadas en las imágenes seccionadas

SUMMARY: The liver dimensional (3D) models, consists of eight segments including portal triad (portal vein, hepatic artery, and bile duct), are necessary because it is difficult to dissect a liver and its inner structures. But it is difficult to produce 3D models from high resolution and color sectioned-images. This study presents automatic and accurate methods for producing liver 3D models from the sectionedimages. Based on the sectioned-images and color-filled-images of the liver, a 3D model including both the portal triad and hepatic vein was made. Referring to the 3D model, 3D models of liver's eight segments including the segmental branches of the portal triad and hepatic vein were completed and saved as STL format. All STL files were combined and saved as Liver-3D in PDF format for the common user. By functional subdivision of liver, the Liver-3D was divided into left (segments II, III, and, IV) and right (segments V, VI, VII, and VIII) liver in bookmark window of the PDF file. In addition, in Liver-3D, the primary to tertiary segmental branches of the portal triad could be shown in different colors. Owing to the difficulty of 3D modeling of liver including eight segments and segmental branches of the portal triad and hepatic, we started this research to find automatic methods for producing 3D models. The methods for producing liver 3D models will assist in 2D selection and 3D modeling of other complicated structures.

RESUMEN: Los modelos hepáticos dimensionales (3D) consisten en ocho segmentos que incluyen la tríada portal (vena porta, arteria hepática y conducto biliar), y son necesarios ya que es difícil disecar un hígado y sus estructuras internas. Sin embargo, es difícil producir modelos 3D a partir de imágenes en alta resolución e imágenes seccionadas en color. Este estudio presenta métodos automáticos y precisos para producir modelos 3D de hígado a partir de las imágenes seccionadas. Sobre la base de las imágenes seccionadas y las imágenes del hígado llenas de color, se realizó un modelo 3D que incluía tanto la tríada portal como la vena hepática. En referencia al modelo 3D, se completaron modelos 3D de los ocho segmentos del hígado que incluían las ramas segmentarias de la tríada portal y la vena hepática y se guardaron como formato STL. Todos los archivos STL fueron combinados y guardados como Liver-3D en formato PDF para el usuario común. Por subdivisión funcional del hígado, el hígado-3D se dividió en hígado izquierdo (segmentos II, III y IV) y derecho (segmentos V, VI, VII y VIII) en la ventana de marcador del archivo PDF. Además, en Liver-3D, las ramas segmentarias primarias a terciarias de la tríada portal podrían mostrarse en diferentes colores. Debido a la dificultad del modelado 3D del hígado, incluidos ocho segmentos y ramas segmentarias de la tríada portal y hepática, comenzamos esta investigación para encontrar métodos automáticos para producir modelos 3D. Los métodos para producir modelos 3D de hígado ayudarán en la selección 2D y el modelado 3D de otras estructuras complicadas.

Aspectos novedosos de la hipertensión portal / Novel aspects of portal hypertension

Fundamento: la hipertensión portal es la complicación más común de la cirrosis que explica una importante morbilidad y mortalidad, principalmente debido a hemorragia por várices esofágicas, la ascitis y sus infecciones bacterianas sobreañadidas, la encefalopatía hepato-amoniacal, y el síndrome hepatorrenal. Los avances en el diagnóstico y su manejo son examinados a continuación en vistas a las perspectivas actuales. Desarrollo: la medición del gradiente de presión de la vena hepática, aporta una importante información pronóstico en estos pacientes. La prueba no invasiva con elastografía, cápsula endoscópica, y tomografía computarizada para el diagnóstico de várices esofágicas son prometedoras pero se necesita más información. Los datos clínicos en pacientes con sangramiento por várices esofágicas proveen una información importante para la terapia inicial y el pronóstico. Las nuevas terapias para pacientes con hiponatremia dilucional con antagonistas de la vasopresina son prometedoras y pueden mejorar el manejo de esta afección. Conclusiones: el terlipressin es la mejor terapia médica actualmente disponible para el manejo del síndrome hepatorrenal como se confirmó recientemente. Los pacientes con la enfermedad hepática avanzada se benefician de la administración por largos períodos del norfloxacin para prevenir el desarrollo del síndrome hepatorrenal y mejorar la supervivencia. Los avances en el diagnóstico y manejo de pacientes con cirrosis e hipertensión portal mejoraran la morbilidad y mortalidad de sus complicaciones(AU)

Background: portal hypertension is the most common complication of cirrhosis that explains an important morbidity and mortality, mainly due to hemorrhage for esophageal varices, ascites and its superadded bacterial infections, the hepato-ammoniacal encephalopathy, and the hepatorenal syndrome. Advances in diagnosis and their management are examined next in view of current perspectives. Development: the pressure gradient mensuration of the hepatic vein, contributes an important prognostic information in these patients. The non invasive test with elastography, endoscopic capsule, and computed tomography for esophageal varices diagnosis are promising but more information is needed. Clinical data in patients with bleeding for esophageal varices provide important information for initial therapy and prognosis. New therapies for patients with dilutional hyponatremia with vasopressin antagonists are promising and may improve this affection management. Conclusions: the terlipressin is currently the best available medical therapy for the hepatorenal syndrome management as has been confirmed recently. Patients with advanced liver disease are benefiting with norfloxacin administration for long periods to prevent hepatorenal syndrome development and to improve survival. Advances in diagnosis and patients management with cirrhosis and portal hypertension improved morbidity and mortality of their complications(AU)

Aspectos novedosos de la hipertensión portal: [revisión] / Novel aspects of portal hypertension: [review]

Fundamento: la hipertensión portal es la complicación más común de la cirrosis que explica una importante morbilidad y mortalidad, principalmente debido a hemorragia por várices esofágicas, la ascitis y sus infecciones bacterianas sobreañadidas, la encefalopatía hepato-amoniacal, y el síndrome hepatorrenal. Los avances en el diagnóstico y su manejo son examinados a continuación en vistas a las perspectivas actuales. Desarrollo: la medición del gradiente de presión de la vena hepática, aporta una importante información pronóstico en estos pacientes. La prueba no invasiva con elastografía, cápsula endoscópica, y tomografía computarizada para el diagnóstico de várices esofágicas son prometedoras pero se necesita más información. Los datos clínicos en pacientes con sangramiento por várices esofágicas proveen una información importante para la terapia inicial y el pronóstico. Las nuevas terapias para pacientes con hiponatremia dilucional con antagonistas de la vasopresina son prometedoras y pueden mejorar el manejo de esta afección. Conclusiones: el terlipressin es la mejor terapia médica actualmente disponible para el manejo del síndrome hepatorrenal como se confirmó recientemente. Los pacientes con la enfermedad hepática avanzada se benefician de la administración por largos períodos del norfloxacin para prevenir el desarrollo del síndrome hepatorrenal y mejorar la supervivencia. Los avances en el diagnóstico y manejo de pacientes con cirrosis e hipertensión portal mejoraran la morbilidad y mortalidad de sus complicaciones.

Background: portal hypertension is the most common complication of cirrhosis that explains an important morbidity and mortality, mainly due to hemorrhage for esophageal varices, ascites and its superadded bacterial infections, the hepato-ammoniacal encephalopathy, and the hepatorenal syndrome. Advances in diagnosis and their management are examined next in view of current perspectives. Development: the pressure gradient mensuration of the hepatic vein, contributes an important prognostic information in these patients. The non invasive test with elastography, endoscopic capsule, and computed tomography for esophageal varices diagnosis are promising but more information is needed. Clinical data in patients with bleeding for esophageal varices provide important information for initial therapy and prognosis. New therapies for patients with dilutional hyponatremia with vasopressin antagonists are promising and may improve this affection management. Conclusions: the terlipressin is currently the best available medical therapy for the hepatorenal syndrome management as has been confirmed recently. Patients with advanced liver disease are benefiting with norfloxacin administration for long periods to prevent hepatorenal syndrome development and to improve survival. Advances in diagnosis and patients’ management with cirrhosis and portal hypertension improved morbidity and mortality of their complications.